Iceland· IS-EU/1/04/275/001-002
Litak
A cladribine product containing cladribinum inn, registered in Iceland by Lipomed GmbH*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Cladribine is registered in 14 of 19 countries.
Countries holding a registration under ATC L01BB04 (cladribine), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Cladribine · ATC L01BB04
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Cladribinum INN
- Manufacturer
- Lipomed GmbH*
- Country
- Iceland (IS)
- ATC code
- L01BB04
- ATC class
- Cladribine
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
409 interactions on record for cladribine.
Graded by severity as the source publishes them — 326 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cladribine · interactions on record
409 records
- 326 severe
- 79 moderate
- 4 info
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cladribine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLEUJECTAtnahs Pharma Netherlands B.V., Amsterdam
- SpainLEUSTATIN 2 MG/ML SOLUCION INYECTABLEAtnahs Pharma Netherlands Bv.
- SwitzerlandLitak 10, Injektions- / InfusionslösungLipomed AG
- PolandLeujectAtnahs Pharma Netherlands B.V.
- SwedenLeuject 2 mg/ml Injektionsvätska, lösningAtnahs Pharma Netherlands B.V.
- BelgiumLitak 2 mg/mlLipomed
- NorwayLitakLipomed GmbH
- United StatesCladribineGenvion Corporation
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Leuject
- Belgium · Leustatin
- Bulgaria · Леуджект
- Czechia · Leuject
- Germany · Leustatin
- Spain · Leustatin
- Finland · Leuject
- France · Leustatine
- United Kingdom (Northern Ireland) · Cladribine Zentiva, Leustat
- Greece · Leustatin
- Croatia · Leuject
- Hungary · Leuject
- Italy · Leustatin
- Liechtenstein · Mavenclad
- Luxembourg · Leustatin
- Netherlands · Leustatin
- Norway · Leuject, Mavenclad
- Poland · Biodribin, Leuject
- Portugal · Cladribina Generis, Leustatin
- Romania · Leuject
- Sweden · Leuject
- Slovenia · Leuject
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/45a5d4f2-2042-4ef4-bbab-9511094aaf45 GET /v1/drugs/45a5d4f2-2042-4ef4-bbab-9511094aaf45?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01BB04",
"marketed": false,
"strength": "2 mg/ml",
"ma_number": "EU/1/04/275/001-002",
"substance": "Cladribinum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "38121"
}See everything about cladribine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.